Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.31 |
| ▸ | GCK | P35557 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480733 | 1.00 | HDAC4 (0.33) | HDAC4SERPINE1GRM4GCKMEN1 | |
| SCHEMBL29480700 | 0.94 | MELK (0.31) | HDAC4 | |
| SCHEMBL29480757 | 0.94 | CYP3A4 (0.31) | HDAC4GCKCYP3A4CYP2D6 | |
| SCHEMBL22736147 | 0.94 | CYP3A4 (0.31) | HDAC4GCKCYP3A4CYP2D6 | |
| SCHEMBL22736348 | 0.91 | MAP3K7 (0.37) | GRM4MEN1KMT2A | |
| SCHEMBL29480761 | 0.91 | MAP3K7 (0.37) | GRM4MEN1KMT2A | |
| SCHEMBL22735756 | 0.89 | CCNT1 (0.35) | — | |
| SCHEMBL29568176 | 0.89 | CCNT1 (0.35) | — | |
| SCHEMBL29480654 | 0.87 | GRM4 (0.35) | HDAC4GRM4GCKKDM4EABL1 | |
| SCHEMBL22735754 | 0.84 | GRM4 (0.34) | HDAC4GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020240586-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2020-12-03 | — | — | WO | disclosed |